Particle.news
Download on the App Store
5 ARTICLES
·
4w ago

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

The deal gives AstraZeneca the commercial scale to broaden access to the EGFR exon 20 insertion drug while first-line approval reviews continue.

Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

Overview

  • AstraZeneca announced an exclusive global license for Zegfrovy on July 14, 2026, agreeing to pay $600 million up front with up to $900 million in milestone payments and tiered royalties.
  • Zegfrovy is already approved in the United States and China for patients with advanced non‑small cell lung cancer who progressed after platinum chemotherapy.
  • Positive Phase III WU‑KONG28 first‑line data were presented at ASCO 2026 and published in The New England Journal of Medicine, and Dizal has filed supplemental NDAs to the U.S. FDA and China’s CDE for a first‑line label.
  • Both the FDA and China CDE have granted Breakthrough Therapy designation for Zegfrovy in the first‑line setting, but formal first‑line approvals are still under review.
  • The transaction is expected to close in the second half of 2026 subject to customary conditions, and AstraZeneca says the deal does not change its 2026 financial guidance while it prepares to integrate Zegfrovy into its lung cancer portfolio.